Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)

G Au-Yeung; PM Webb; A Defazio; S Fereday; M Bressel; L Mileshkin

Journal article

Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)

G Au-Yeung, PM Webb, A Defazio, S Fereday, M Bressel, L Mileshkin

Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2014

DOI: 10.1016/j.ygyno.2014.01.030

Abstract

Obesity is an increasing health problem that is reported to influence chemotherapy dosing. The extent to which this occurs and whether this affects outcomes in ovarian cancer was unclear. To describe chemotherapy dosing practices in normal, overweight and obese patients treated for FIGO Stage III/IV serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). To evaluate the relationship between body mass index (BMI), dose intensity of chemotherapy received, overall survival (OS) and progression free survival (PFS). Methods Patient characteristics including age, height, weight, FIGO stage, serum creatinine, primary chemotherapy received and outcome data were extracted from medical re..

View full abstract

University of Melbourne Researchers

George Au-Yeung Author

Julie Fereday Author

Mathias Azevedo Bastian Bressel Author

Linda Mileshkin Author

Related Projects (3)

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Grants

Awarded by U.S. Army Medical Command

Funding Acknowledgements

AOCS was supported by the U.S. Army Medical Research and Material Command under DAMD-17-01-1-0729, the Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, the Cancer Foundation of Western Australia, The Cancer Council Tasmania and the National Health and Medical Research Council of Australia (Enabling Grant 400413 and Project Grant 400281). PW is supported by a fellowship from the National Health and Medical Research Council.